See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

More biotechs announce share buybacks; Cosette to buy Mayne Pharma

Summary by Endpoints News
Exelixis and Neurocrine each announce $500M share buybacks; Cosette buys Mayne for $430M; MeiraGTx seeks UK approval for blindness gene therapy; Hookipa ends Poolbeg talks.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Endpoints NewsEndpoints News

More biotechs announce share buybacks; Cosette to buy Mayne Pharma

Exelixis and Neurocrine each announce $500M share buybacks; Cosette buys Mayne for $430M; MeiraGTx seeks UK approval for blindness gene therapy; Hookipa ends Poolbeg talks.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United Kingdom

United Kingdom

News
For You
Search
BlindspotLocal